Clinical trials recruiting in White Plains, New York

Phase breakdown

Conditions recruiting in White Plains, New York

Recruiting trials in White Plains, New York

• A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
  NCT07365995 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Primary Care-Based Psychosocial Intervention To Improve Cognitive & Depression Outcomes in Older Adults With MCI & Early Stage AD
  NCT05081596 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female)
• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
  NCT07365319 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
  NCT06875310 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
  NCT05774951 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female)
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
  NCT07409272 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  NCT07144280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
  NCT07434479 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female)
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  NCT06058377 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
  NCT07357597 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
  NCT03907046 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
  NCT06773910 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
  NCT07379827 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Mind-Body Skills Group for Graduate Students
  NCT05447689 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Pancreatic Cancer Early Detection Consortium
  NCT04970056 · Phase: Not specified · Ages: 18 Years to 90 Years · Sex: All (male and female)
• Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
  NCT07228832 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
  NCT03418961 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
  NCT06712355 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Study of ALTO-101 in Patients With Schizophrenia
  NCT06502964 · Phase: Phase 2 · Ages: 21 Years to 55 Years · Sex: All (male and female)
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
  NCT03191149 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
  NCT05836987 · Phase: Phase 3 · Ages: 22 Years to 85 Years · Sex: All (male and female)
• WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
  NCT05183230 · Phase: Not applicable (e.g. observational or device study) · Ages: 50 Years to 90 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in White Plains, New York?

30 recruiting trials have at least one study site in White Plains, New York.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.